The National Institute for Health and Care Excellence (NICE) has published final draft guidance enabling AbbVie’s Aquipta (atogepant) to be commissioned by the National Health Service (NHS) in England and Wales as an acute treatment for migraine attacks. The regulatory green light comes just a few weeks after the Medicines and Healthcare products Regulatory Agency (MHRA) authorized the drug’s acute indication, complementing a prior NICE recommendation for migraine prophylaxis established two years ago.
The documented clinical access criteria, ECLIPSE Phase 3 trial data, and product commercial metrics feature:
-
Clinical Eligibility Framework and Local Commissioning Barriers:
-
Patient Access Criteria: Under the definitive NICE guidelines, Aquipta is made available for the acute treatment of migraine in patients who have derived insufficient therapeutic relief from at least two prior triptan medications, or in whom triptans are clinically contraindicated or poorly tolerated, and who also fail to achieve pain reduction from standard analgesics such as paracetamol.
-
Regional Access Disparities: Rob Music, Chief Executive of The Migraine Trust, welcomed the clinical option but cautioned that prescribing workflows remain subject to localized commissioning through regional Integrated Care Boards (ICBs). He noted this operational barrier historically creates a geographic “postcode lottery,” emphasizing the urgent need for swift, consistent drug availability across both primary and secondary healthcare delivery channels.
-
-
Efficacy Metrics From the Phase 3 ECLIPSE Clinical Trial:
-
The expansion into acute reimbursement is structurally supported by data generated from the pivotal Phase 3 ECLIPSE clinical trial evaluating therapeutic performance following an initial migraine attack.
-
The study demonstrated that 24.3% of patient cohorts treated with atogepant achieved complete pain-free status two hours post-dosing, benchmarked against a lower 13.1% response rate recorded in the placebo control arm.
-
-
Commercial Positioning and Global Pipeline Expansion for AbbVie:
-
Blockbuster Revenue Performance: Aquipta operates as an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist. Marketed within the United States jurisdiction under the brand name Qulipta, AbbVie claims the asset functions as the leading oral CGRP brand for migraine prevention, outpacing its primary market rival, Pfizer’s Nurtec ODT (rimegepant). Qulipta/Aquipta secured blockbuster status by logging $1.03 billion in global sales last fiscal year, while AbbVie’s parallel acute CGRP inhibitor, Ubrelvy (ubrogepant), generated an additional $1.27 billion.
-
Forward Clinical Timelines: AbbVie is actively evaluating both Aquipta and Ubrelvy in Phase 3 trials for the prevention of menstrual migraine—a severe, highly refractory disease subtype affecting nearly 15% of female migraine patients. Definitive data readouts are projected for the second half of this year, positioned to trigger regulatory submissions in Europe before the end of 2026 and within the United States in early 2027.
-
Source: https://pharmaphorum.com/news/abbvies-migraine-drug-cleared-migraine-attacks-nhs